Seer Retains 23 Claims in U.S. Proteograph Patent, Bolsters IP Portfolio
The Patent Trial and Appeal Board upheld 23 of 29 claims in U.S. Patent No. 11,435,360 B2, securing protection for Seer's nano- and microparticle protein enrichment technology underlying its Proteograph Product Suite. The decision preserves core methods for detecting proteins across wide concentration ranges, reinforcing Seer's competitive edge in proteomics.
1. PTAB Upholds Majority of ’360 Patent Claims
On March 23, 2026, the Patent Trial and Appeal Board issued a Final Written Decision upholding 23 of 29 claims of U.S. Patent No. 11,435,360 B2, which protects Seer's engineered nano- and microparticle protein enrichment methods.
2. Coverage of Enrichment Methods
The upheld claims cover methods for forming protein coronas on engineered particles and detecting proteins across wide concentration ranges, core capabilities that underpin the Proteograph Product Suite’s deep proteomic analysis of cells, tissues and biofluids.
3. Strengthened IP Portfolio
This ruling strengthens Seer’s intellectual property portfolio, which includes over 240 issued patents and pending applications, enhancing barriers to entry for competitors and supporting Seer’s ongoing investments in scalable proteomics technologies.
4. Challenge by Bruker Subsidiaries
The inter partes review was filed by PreOmics GmbH and Biognosys AG, subsidiaries of Bruker Corporation, challenging 11 claims, but all five contested claims remained valid, confirming the robustness of Seer’s patent protection.